BioAge Labs, Inc. (BIOA)
(Real Time Quote from BATS)
$4.33 USD
+0.21 (5.10%)
Updated Aug 4, 2025 02:16 PM ET
3-Hold of 5 3
D Value F Growth B Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
BIOA 4.33 +0.21(5.10%)
Will BIOA be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for BIOA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for BIOA
BioAge Labs, Inc. (BIOA) Loses -67.99% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Biotech Stock Roundup: BIOA Down on Study Update, QURE, CRDF Gain on Study Data & More
BIOA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for BIOA
BioArtic: Latest data presented at AAIC 2025 reinforces lecanemab's clinical effect with ...
Lecanemab four-year efficacy and safety data to be presented at AAIC 2025 | BIOA Stock News
The drug discovery research for lecanemab awarded the 9th Bioindustry Award by the Japan ...
BIOA Crosses Above Average Analyst Target